Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin (2022 - 2025)

Axsome Therapeutics' FCF Margin history spans 4 years, with the latest figure at 9.55% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1253.0% year-over-year to 9.55%; the TTM value through Dec 2025 reached 14.7%, up 1866.0%, while the annual FY2025 figure was 14.7%, 1866.0% up from the prior year.
  • FCF Margin for Q4 2025 was 9.55% at Axsome Therapeutics, down from 0.58% in the prior quarter.
  • Across five years, FCF Margin topped out at 0.58% in Q3 2025 and bottomed at 382.97% in Q2 2022.
  • The 4-year median for FCF Margin is 35.3% (2024), against an average of 69.3%.
  • The largest annual shift saw FCF Margin surged 26417bps in 2023 before it plummeted -6519bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 113.84% in 2022, then soared by 63bps to 42.46% in 2023, then soared by 48bps to 22.09% in 2024, then surged by 57bps to 9.55% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's FCF Margin are 9.55% (Q4 2025), 0.58% (Q3 2025), and 21.62% (Q2 2025).